Zhengye Biotechnology Holding Limited (NASDAQ:ZYBT) Sees Significant Decrease in Short Interest

Zhengye Biotechnology Holding Limited (NASDAQ:ZYBT) saw a significant decline in short interest in the month of June. As of June 30th, there was short interest totaling 43,518 shares, a decline of 59.8% from the June 15th total of 108,354 shares. Based on an average trading volume of 20,766 shares, the short-interest ratio is presently 2.1 days. Approximately 0.1% of the shares of the company are sold short.

Zhengye Biotechnology Stock Performance

NASDAQ ZYBT opened at $0.74 on Tuesday. The business has a 50-day moving average price of $0.83 and a 200-day moving average price of $0.93. Zhengye Biotechnology has a twelve month low of $0.62 and a twelve month high of $13.08. The company has a quick ratio of 0.82, a current ratio of 1.14 and a debt-to-equity ratio of 0.03.

Zhengye Biotechnology (NASDAQ:ZYBT) last released its earnings results on Tuesday, April 28th. The company reported ($0.08) EPS for the quarter. The firm had revenue of $3.97 million for the quarter.

Analyst Ratings Changes

Separately, Weiss Ratings cut shares of Zhengye Biotechnology from a “sell (d)” rating to a “sell (d-)” rating in a report on Thursday, June 11th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, Zhengye Biotechnology presently has an average rating of “Sell”.

Hedge Funds Weigh In On Zhengye Biotechnology

Several large investors have recently modified their holdings of ZYBT. Citadel Advisors LLC bought a new position in Zhengye Biotechnology during the 3rd quarter valued at about $31,000. XTX Topco Ltd grew its stake in Zhengye Biotechnology by 71.4% in the 4th quarter. XTX Topco Ltd now owns 59,286 shares of the company’s stock worth $68,000 after acquiring an additional 24,697 shares in the last quarter. Jane Street Group LLC bought a new position in Zhengye Biotechnology in the second quarter worth approximately $1,158,000. Invesco Ltd. purchased a new position in shares of Zhengye Biotechnology during the second quarter valued at $220,000. Finally, Geode Capital Management LLC bought a new position in Zhengye Biotechnology during the 2nd quarter worth about $174,000.

About Zhengye Biotechnology

Zhengye Biotechnology Holding Limited is a veterinary vaccine manufacturer which encompasses research, development, manufacturing and sales of veterinary vaccines, with a focus on livestock vaccine principally in China. Zhengye Biotechnology Holding Limited is based in Jilin, China.